Literature DB >> 20459532

Clinicopathological correlates and prognostic significance of maspin expression in 450 patients after potentially curative resection of node-positive colonic cancer.

Caroline L-S Fung1, Charles Chan, Lucy Jankova, Owen F Dent, Graham Robertson, Mark Molloy, Les Bokey, Pierre H Chapuis, Betty P C Lin, Stephen J Clarke.   

Abstract

AIMS: The tumour suppressor maspin has been investigated for its association with conventional histopathological features in colorectal cancer and for its potential as an independent predictor of survival and response to adjuvant chemotherapy. The aim of this study was to examine associations between maspin expression, other histopathology and survival in a large consecutive series of patients after potentially curative resection of node-positive colonic adenocarcinoma. METHODS AND
RESULTS: Nuclear and cytoplasmic maspin expression in both superficial and deep parts of the tumour were assessed retrospectively by tissue microarray and immunohistochemistry in specimens from 450 patients whose other histopathology had been recorded in a prospective hospital registry of large bowel cancer resections from 1971 to 2001 with a minimum follow-up of 5 years. Among 13 clinicopathological features examined, the only associations that persisted across all four maspin assessments were stronger expression in right- than in left-sided tumours (P=0.001-0.011) and stronger expression in high-grade tumours (P<0.001-0.007). There was no significant association between intensity of maspin expression and overall survival.
CONCLUSIONS: In this large and thoroughly documented series of patients with clinicopathological stage C colonic tumour, maspin expression was correlated with few other conventional histopathology variables and was not a significant prognostic factor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20459532     DOI: 10.1111/j.1365-2559.2010.03479.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  6 in total

1.  Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.

Authors:  Jung Ho Kim; Nam-Yun Cho; Jeong Mo Bae; Kyung-Ju Kim; Ye-Young Rhee; Hye Seung Lee; Gyeong Hoon Kang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

2.  Overexpression of protein S100A4 is independently associated with overall survival in stage C colonic cancer but only in cytoplasm at the advancing tumour front.

Authors:  P S S Kho; L Jankova; C L-S Fung; C Chan; C Clarke; B P C Lin; G Robertson; M Molloy; P H Chapuis; E L Bokey; O F Dent; S Clarke
Journal:  Int J Colorectal Dis       Date:  2012-05-09       Impact factor: 2.571

3.  Maspin is a marker for early recurrence in primary stage III and IV colorectal cancer.

Authors:  N Snoeren; B L Emmink; M J G Koerkamp; S R van Hooff; J A C M Goos; W J van Houdt; M de Wit; A M Prins; S R Piersma; T V Pham; E J Belt; H Bril; H B Stockmann; G A Meijer; R van Hillegersberg; F C Holstege; C R Jimenez; R J A Fijneman; O W Kranenburg; I H M Borel Rinkes
Journal:  Br J Cancer       Date:  2013-09-03       Impact factor: 7.640

4.  Proteomic profiling of antibody-inducing immunogens in tumor tissue identifies PSMA1, LAP3, ANXA3, and maspin as colon cancer markers.

Authors:  Qian Yang; Michael H Roehrl; Julia Y Wang
Journal:  Oncotarget       Date:  2017-12-22

Review 5.  Subcellular Expression of Maspin in Colorectal Cancer: Friend or Foe.

Authors:  Simona Gurzu; Ioan Jung
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

6.  Role of maspin in cancer.

Authors:  Rossana Berardi; Francesca Morgese; Azzurra Onofri; Paola Mazzanti; Mirco Pistelli; Zelmira Ballatore; Agnese Savini; Mariagrazia De Lisa; Miriam Caramanti; Silvia Rinaldi; Silvia Pagliaretta; Matteo Santoni; Chiara Pierantoni; Stefano Cascinu
Journal:  Clin Transl Med       Date:  2013-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.